ASCO addresses financial barriers to cancer clinical trials

Print Friendly, PDF & Email


Preparing drug for a trial
Photo by Esther Dyson
The American Society of Clinical Oncology (ASCO) has issued a policy statement addressing financial barriers to patient participation in cancer clinical trials. ASCO’s policy statement outlines a series of recommendations designed to address multiple financial barriers that impede access to clinical trials, including patient costs that... [Read Article]
Print Friendly, PDF & Email

Doc reports ‘very encouraging’ results in penta-refractory MM

Print Friendly, PDF & Email


Vials of drugs
Photo by Bill Branson
Treatment with selinexor and low-dose dexamethasone can provide a “meaningful clinical benefit” in patients with penta-refractory multiple myeloma (MM), according to the principal investigator of the STORM trial. Updated results from this phase 2 trial showed that selinexor and low-dose dexamethasone produced an overall response rate of... [Read Article]
Print Friendly, PDF & Email

CAR T-cell therapy elicits responses in MM

Print Friendly, PDF & Email


Micrograph showing
multiple myeloma
Early results from a phase 1 trial suggest the chimeric antigen receptor (CAR) T-cell therapy P-BCMA-101 can produce responses in patients with relapsed/refractory multiple myeloma (MM). All 11 patients treated have experienced some clinical response, with 8 patients achieving a partial response (PR) or better. The most common adverse events... [Read Article]
Print Friendly, PDF & Email

Kids with BCP-ALL exhibit immunological disparities at birth

Print Friendly, PDF & Email


Smiling baby
Photo by Petr Kratochvil
Patients who develop B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in childhood may have dysregulated immune function at birth, according to a study published in Cancer Research. Investigators evaluated neonatal concentrations of inflammatory markers and found significant differences between children who were later diagnosed with BCP-ALL and leukemia-free control... [Read Article]
Print Friendly, PDF & Email

FDA approves drug for hairy cell leukemia

Print Friendly, PDF & Email


Hairy cell leukemia
Image from Paulo
Henrique Orlandi Mourao
The U.S. Food and Drug Administration (FDA) has approved moxetumomab pasudotox-tdfk (Lumoxiti), a CD22-directed cytotoxin, to treat hairy cell leukemia (HCL). Moxetumomab pasudotox is approved to treat adults with relapsed or refractory HCL who have received at least two prior systemic therapies, including treatment... [Read Article]
Print Friendly, PDF & Email

EC approves product for von Willebrand disease

Print Friendly, PDF & Email


US version of vonicog alfa
Photo from Shire
The European Commission (EC) has granted marketing authorization for vonicog alfa (Veyvondi), a recombinant von Willebrand factor (rVWF) product. The EC approved vonicog alfa for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with von Willebrand disease... [Read Article]
Print Friendly, PDF & Email

Insights could change treatment, classification of MPAL

Print Friendly, PDF & Email


From left to right: Study
authors Ilaria Iacobucci,
Charles Mullighan, Hiroto
Inaba, and Zhaohui Gu
Photo from St. Jude
Children’s Research Hospital
An extensive analysis of mixed phenotype acute leukemia (MPAL) has led to new insights that may have implications for disease classification and treatment. Researchers believe they have identified new subtypes of MPAL... [Read Article]
Print Friendly, PDF & Email

MRD data added to venetoclax label

Print Friendly, PDF & Email


First month’s supply of
venetoclax (Venclexta)
Photo courtesy of Abbvie
The U.S. Food and Drug Administration (FDA) has expanded the label for venetoclax tablets (Venclexta®) to include data on minimal residual disease (MRD). The drug’s prescribing information now includes details on MRD negativity in previously treated patients with chronic lymphocytic leukemia (CLL) who received venetoclax... [Read Article]
Print Friendly, PDF & Email

Cell population appears to drive relapse in AML

Print Friendly, PDF & Email


From left to right: Study authors Lili Aslostovar, Allison Boyd, and Mick Bhatia
Photo by Kevin Patrick Robbins/McMaster University
Researchers believe they have identified cells that are responsible for relapse of acute myeloid leukemia (AML). These “leukemic-regenerating cells” (LRCs), which are distinct from leukemic stem cells (LSCs), seem to arise in response to chemotherapy. Experiments... [Read Article]
Print Friendly, PDF & Email

HIF1A could be therapeutic target for MDS

Print Friendly, PDF & Email


Lab mouse
The transcription factor HIF1A could be a therapeutic target for “a broad spectrum” of patients with myelodysplastic syndromes (MDS), according to researchers. Preclinical experiments indicated that HIF1A fuels the biological processes that cause different types of MDS. Researchers also found that inhibiting HIF1A reversed MDS symptoms and prolonged survival in mouse models of... [Read Article]
Print Friendly, PDF & Email

Hemophilia B drug available in larger vial

Print Friendly, PDF & Email


Antihemophilic factor
CSL Behring has announced that Idelvion (Coagulation Factor IX [Recombinant], Albumin Fusion Protein) is now available in a 3500 IU vial size. Idelvion is also available in 250 IU, 500 IU, 1000 IU, and 2000 IU vial sizes. For some patients requiring high doses of Idelvion, the new 3500 IU vial size... [Read Article]
Print Friendly, PDF & Email

Team identifies potential immunotherapy target for AML

Print Friendly, PDF & Email


Ben Vincent, MD
Photo from the University
of North Carolina
New research could aid the development of immunotherapies tailored to patients with acute myeloid leukemia (AML) who are undergoing stem cell transplant (SCT). Researchers found they could use genetic sequencing and computer software to identify minor histocompatibility antigens (mHAs) known to occur in AML. The... [Read Article]
Print Friendly, PDF & Email

Mechanism of cGVHD response to ECP still unclear

Print Friendly, PDF & Email


Micrograph showing GVHD
Image from PLOS ONE
A prospective study did not reveal the mechanism driving response to extracorporeal photopheresis (ECP) in patients with chronic graft-versus-host disease (cGVHD). However, researchers did find that responses occurred independent of risk factors, and results suggested that regulatory T cells (Tregs) are not the dominant mechanism of response to... [Read Article]
Print Friendly, PDF & Email

First CAR T-cell therapy approved in Canada

Print Friendly, PDF & Email


Micrograph showing ALL
Health Canada has authorized use of tisagenlecleucel (Kymriah), making it the first chimeric antigen receptor (CAR) T-cell therapy to receive regulatory approval in Canada. Tisagenlecleucel (formerly CTL019) is approved to treat patients ages 3 to 25 with B-cell acute lymphoblastic leukemia (ALL) who have relapsed after allogeneic stem cell transplant (SCT) or... [Read Article]
Print Friendly, PDF & Email

CAR T-cell therapy will soon be available in England, NHS says

Print Friendly, PDF & Email


Tisagenlecleucel (Kymriah)
Photo from Novartis
The National Health Service (NHS) of England has announced that tisagenlecleucel (Kymriah®), a chimeric antigen receptor (CAR) T-cell therapy, will soon be available for certain leukemia patients. Tisagenlecleucel will be made available through the Cancer Drugs Fund, and patients could potentially begin receiving the treatment within weeks. NHS England struck... [Read Article]
Print Friendly, PDF & Email